Everyday HealthCancer Patients See Sustained Response to COVID Vaccine

Source: MedPage Today (from JAMA Oncology)
Design: Analysis was from a previously published prospective cohort study that evaluated the rates of antibody response to Pfizer’s vaccine in 102 cancer patients who were on active treatment compared with 78 healthy controls. A fourth of the patients were undergoing treatment for lung cancer, 26% for gastrointestinal cancers, and 18% for breast cancer.
Results: After four months from the second dose of Pfizer’s mRNA vaccine, 87% of cancer patients who had been on active treatment continued to produce COVID-19 antibodies.